The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM).

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.29.15_SUPPL.2021PMID 28023840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Drug-induced hypertension is associated with improved survival in glioblastoma patients treated with bevacizumab: evidence from a time-to-event meta-analysis and meta-regression

  2026cites this paper
• Prognostic value of hypertension timing for survival in glioblastoma patients receiving bevacizumab: a retrospective single centre analysis

  2025cites this paper
• Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients

  2020influential citation
• Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials

  2020cites this paper
• Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

  2016cites this paper
• Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature

  2013cites this paper
• Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date

  2012cites this paper
• Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy

  2012cites this paper
• Bevacizumab in glioblastoma

  2012cites this paper
• Bevacizumab in glioblastoma multiforme

  2012cites this paper
• Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC.

  2012cites this paper